Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Lutetium 177-labeled DOTA Complex (177Lu-DOTA Complex)
- Target
- 177Lu-DOTA Complex
- Molecular classification
- Radiopharmaceutical, Metal chelate complex, Somatostatin analog conjugate
01
Overview
Lutetium-177-labeled DOTA complexes are radiopharmaceutical agents designed for targeted cancer therapy. They consist of the radioactive isotope lutetium-177 chelated by DOTA and conjugated to a targeting moiety, typically a somatostatin analog. The complex selectively binds to somatostatin receptors overexpressed on tumor cells, leading to internalization and subsequent beta particle emission, causing DNA damage and cytotoxicity. The most common clinical application is in the treatment of neuroendocrine tumors using Lutetium-177 dotatate (Lutathera).
- Other names
- Lutetium-177 dotatateLutathera177Lu-DOTATATE177Lu-DOTA-TATEDOTA-TATE/EB-TATE
02
Mechanism of action
Selective binding to somatostatin receptors (SSTR2) on tumor cells, followed by internalization and beta particle-induced DNA damage.
03
Biological functions
Targeted radiotherapySomatostatin receptor bindingDNA damage inductionTumor cell cytotoxicity
04
Disease associations
CancerNeuroendocrine tumors
05
Safety considerations
Radiation exposureBone marrow toxicityKidney toxicity
06
Biomarkers
Somatostatin receptor expression (SSTR2)
Beyond the preview
Go deeper on Lutetium 177-labeled DOTA Complex (177Lu-DOTA Complex).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lutetium 177-labeled DOTA Complex (177Lu-DOTA Complex).